Skip to main content

Table 1 Baseline characteristics in case control study of cardiac events associated with PI therapy

From: Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

  Cases
N = 21
Controls
N = 75
Years of age, median (range) 63 (46–86) 59 (36–91)
Male, n (%) 11 (52) 51 (68)
Caucasian, n (%) 13 (62) 60 (80)
Current or past smoker, n (%) 11 (52) 30 (40)
Dyslipidemia, n (%) 8 (38) 18 (24)
Type II diabetes, n (%) 5 (24) 9 (12)
Kidney disease, n (%) 3 (14) 7 (9)
10-Year ASCVD risk >20%, n (%) 7 (37) 8 (14)
Prior cardiac event, n (%) 16 (76) 41 (55)
 Atrial fibrillation/flutter, n (%) 3 (14) 2 (3)
 CAD, n (%) 3 (14) 3 (4)
 Heart failure, n (%) 4 (19) 0 (0)
 Hypertension, n (%) 15 (71) 38 (51)
 Venous/arterial thromboembolism, n (%) 3 (14) 4 (5)
 Valvular disease, n (%) 2 (10) 1 (1)
ACE inhibitor or ARB use, n (%) 8 (38) 24 (32)
Antithrombotic use, n (%) 11 (52) 22 (29)
Beta blocker use, n (%) 11 (52) 11 (15)
Lipid lowering agent use, n (%) 14 (67) 17 (23)
Loop diuretic use, n (%) 4 (19) 4 (5)
Followed by cardio-oncologist 7 (33) 16 (21)
Durie Salmon stage III, n (%) 11 (52) 47 (63)
International Staging System III, n (%) 5 (24) 23 (31)
Cytogenetic/FISH high risk, n (%) 2 (10) 8 (11)
Received bortezomib only, n (%) 7 (33) 37 (49)
Received carfilzomiba, n (%) 14 (67) 38 (51)
Total days of PI therapy, median (range) 407 (38–1032) 250 (2–885)
  1. Abbreviations: PI proteasome inhibitor, ASCVD atherosclerotic cardiovascular disease, CAD coronary artery disease, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, FISH fluorescent in situ hybridization
  2. aAll patients previously received bortezomib